S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:AUTL - Autolus Therapeutics Stock Price, Forecast & News

$5.63
+0.19 (+3.49 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$5.23
Now: $5.63
$5.76
50-Day Range
$4.20
MA: $8.10
$11.18
52-Week Range
$3.00
Now: $5.63
$32.84
Volume88,256 shs
Average Volume183,918 shs
Market Capitalization$226.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Read More
Autolus Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
CUSIPN/A
CIKN/A
Phone44-20-3829-6230

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 million
Book Value$6.35 per share

Profitability

Net Income$-123,850,000.00
Net Margins-4,258.87%

Miscellaneous

EmployeesN/A
Market Cap$226.04 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.


Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

How has Autolus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have decreased by 16.8% and is now trading at $5.63. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Autolus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Autolus Therapeutics.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics Ltd - (NASDAQ:AUTL) issued its earnings results on Tuesday, March, 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.10. The business had revenue of $0.31 million for the quarter, compared to analysts' expectations of $2 million. Autolus Therapeutics had a negative net margin of 4,258.87% and a negative return on equity of 47.61%. View Autolus Therapeutics' earnings history.

What price target have analysts set for AUTL?

3 equities research analysts have issued 12 month price targets for Autolus Therapeutics' stock. Their forecasts range from $24.00 to $26.00. On average, they anticipate Autolus Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 344.0% from the stock's current price. View analysts' price targets for Autolus Therapeutics.

What are Wall Street analysts saying about Autolus Therapeutics stock?

Here are some recent quotes from research analysts about Autolus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (2/4/2020)
  • 2. HC Wainwright analysts commented, "Our $24 price target, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.50, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.4%, and tax rate of 15% beginning in FY 2028. Our rNPV for: (1) AUTO3 is $17; (2) AUTO1 is $4; and (3) AUTO4 is $3, which are derived from probability adjusted peak sales of: (1) $432M; (2) $150M; and (3) $96M, respectively." (9/12/2019)

Has Autolus Therapeutics been receiving favorable news coverage?

News stories about AUTL stock have trended very positive on Monday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Autolus Therapeutics earned a news impact score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAutolus Therapeutics.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 55)
  • Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
  • Mr. Christopher Vann, Sr. VP & COO (Age 55)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital World Investors (5.47%), Schroder Investment Management Group (5.22%), Marshall Wace LLP (1.69%), Victory Capital Management Inc. (0.86%), Point72 Asset Management L.P. (0.79%) and Victory Capital Management Inc. (0.62%).

Which institutional investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Goldman Sachs Group Inc., Renaissance Technologies LLC, and TD Asset Management Inc..

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Capital World Investors, Point72 Asset Management L.P., Marshall Wace LLP, Victory Capital Management Inc., Alyeska Investment Group L.P., Vident Investment Advisory LLC, and SG Americas Securities LLC.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $5.63.

How big of a company is Autolus Therapeutics?

Autolus Therapeutics has a market capitalization of $226.04 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.  View additional information about Autolus Therapeutics.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is http://www.autolus.com/.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]


MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel